Categories
South Korea Market

Nafabeltan out, but push for homegrown COVID-19 drug continues

Sumary of Nafabeltan out, but push for homegrown COVID-19 drug continues:

  • The competition to develop the country second COVID-19 treatment continues among South Korea major pharmaceutical companies after Chong Kun Dang Pharmaceutical recently dropped out…
  • South Korea Ministry of Food and Drug Safety announced Wednesday that it has decided not to approve Chong Kun Dang Pharmaceutical candidate, Nafabeltan, based on a review by its advisory board of its efficacy and safety…
  • Chong Kun Dang Pharmaceutical acute pancreatitis drug was one of two strong candidates to become the country No…
  • 2 treatment for COVID-19, following Rekirona by Celltrion, which became the first commercially available therapy developed by a local firm in February…
  • Now, the next in line is GC Pharma blood plasma-derived therapy, GC5131A, which is intended to treat more serious COVID-19 cases….

Want to know more click here go to source.